公司名稱: 金嗓子控股集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定 ...

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

公告称，集团收益减少主要是由于2025年上半年行业形势的改变，集团产品营销策略调整，使得客户经 销商2025年上半年减少了采购所致。 金嗓子(06896)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益3.19亿元，同比减少 39.14%;净利润8367.4万元，同比减少37.65%;每股基本亏损11.32分。 金嗓子 分时图 日K线 周K线 月K线 3.62 0.00 0.00% 1.66% 1.10% 0.55% 0.00% 0.55% 1.10% 1.66% 3.56 3.58 3.60 3.62 3.64 3.66 3.68 09:30 10:30 12:00/13:00 14:00 16:10 0 4万 8万 11万 ...

格隆汇8月28日丨金嗓子(06896.HK)公告，截至2025年6月30日止六个月，集团收益减少约人民币205.3 百万元或39.1%至约人民币319.2百万元。集团的除息税、折旧及摊销前盈利较截至2024年6月30日止六 个月减少约人民币69.7百万元或35.6%至约人民币125.9百万元。公司权益持有人应占溢利较截至2024年 6月30日止六个月减少约人民币50.5百万元或37.6%至约人民币83.7百万元。 ...

智通财经APP讯，金嗓子(06896)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益3.19亿 元，同比减少39.14%;净利润8367.4万元，同比减少37.65%;每股基本亏损11.32分。 公告称，集团收益减少主要是由于2025年上半年行业形势的改变，集团产品营销策略调整，使得客户经 销商2025年上半年减少了采购所致。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 金嗓子控股集團有限公司 （根據開曼群島法律註冊成立的成員責任有限公司） • 本集團的收益較截至2024年6月30日止六個月減少約人民幣205.3百萬元或39.1%至 約人民幣319.2百萬元。 • 本集團的毛利較截至2024年6月30日止六個月減少約人民幣145.5百萬元或37.1%至 約人民幣246.3百萬元。 • 本集團的除息稅、折舊及攤銷前盈利較截至2024年6月30日止六個月減少約人民 幣69.7百萬元或35.6%至約人民幣125.9百萬元。 • 本公司權益持有人應佔溢利較截至2024年6月30日止六個月減少約人民幣50.5百萬 元或37.6%至約人民幣83.7百萬元。 • 董事會不建議宣派任何截至2025年6月30日止六個月的中期股息。 業績 金嗓子控股集團有限公司董事會謹此宣佈本公司及其附屬公司截至20 ...

格隆汇8月18日丨金嗓子(06896.HK)宣布，董事会会议将于2025年8月28日（星期四）举行，藉以（其中 包括）审议及批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，并考虑宣派 及派发中期股息（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 金嗓子控股集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會議將於2025 年8月28日（星期四）舉行，藉以（其中包括）審議及批准本公司及其附屬公司截至2025年6 月30日止六個月之中期業績及其發佈，並考慮宣派及派發中期股息（如有）。 承董事會命 金嗓子控股集團有限公司 主席 江佩珍 中國廣西 2025年8月18日 6896 董事會會議通告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.43條而作出。 於本公告日期，董事會成員包括非執行董事江佩珍女士；執行董事曾勇先生、黃建平先 生、曾克雄先生及何錦強先生；及獨立非執行董事李驊先生、朱頡榕先生、程益群先生 及覃解生先生。 ...

Group 1: Hong Kong Stock Market Performance - Zhengda Enterprise International (03839) surged over 20% after reporting a revenue of approximately $323 million, a year-on-year increase of 199.44%, and a net profit attributable to shareholders of $17.046 million, up 768.36% [2] - Zhenjiu Lidu (06979) rose over 11% as research indicated that the liquor industry is moving towards a performance bottom, with expectations for a trend reversal in stock prices ahead of demand recovery [2] - Lithium stocks fell, with Tianqi Lithium (09696) down over 7.5% and Ganfeng Lithium (01772) down over 5.7%, due to anticipated long-term production halts affecting domestic lithium carbonate output by nearly 12% [2] - China General Nuclear Power (01816) increased over 3% as it plans to commission multiple nuclear units between 2025 and 2030, with expectations of a long-term price rebound in the Guangdong region [2] Group 2: Company Earnings Reports - Hillstone Technology (01478) reported a revenue of 8.832 billion RMB for the first half of the year, a year-on-year increase of 15.1%, and a net profit of 308 million RMB, up 167.6% [4] - Jinsongzi (06896) fell nearly 20% after issuing a profit warning, expecting a profit decrease of about 37% compared to the same period in 2024 [4] - Jinke Services (09666) rose over 7% after announcing an expected net profit of approximately 0 to 100 million RMB for the six months ending June 30, 2025, compared to a net loss of 194.4 million RMB in the same period last year [4] - Jingtai Holdings (02228) increased nearly 5%, forecasting a comprehensive income of no less than 500 million RMB for the first half of 2025, a year-on-year increase of at least 387% [4] Group 3: U.S. Stock Market Highlights - AMD (AMD.US) fell 0.28% after confirming it received preliminary approval for AI chip exports to China [6] - TSMC (TSM.US) rose 0.11% with July sales reaching approximately $10.806 billion, a year-on-year increase of 25.8% [6] - Micron Technology (MU.US) increased by 4.06% after raising its revenue guidance for Q4 2025 to $11.1 billion to $11.3 billion, citing improved DRAM pricing conditions [6] - Intel (INTC.US) rose 3.51% amid news of CEO Pat Gelsinger's planned discussions with the White House [7] Group 4: Emerging Companies and Innovations - Tesla (TSLA.US) rose 2.85% after applying for a power supply license in the UK, aiming to compete with local energy giants [8] - Bilibili (BILI.US) increased by 1.67%, with a report highlighting that 70% of China's Z+ generation are users of the platform, indicating strong user engagement [8] - XPeng Motors (XPEV.US) continued to rise by 5.84% as its new extended-range model entered the new vehicle announcement list, indicating an upcoming launch [8]

【财华社讯】截至发稿，金嗓子(06896.HK)跌20.81%，报3.92港元，消息面上，该公司公布盈利预警， 截至预期2025年6月30日止六个月，溢利同比减少约37%。主要由于2025年上半年行业形势的改变，集 团产品营销策略调整，使得客户经销商减少了采购，导致销售额及溢利有所下降。 本文源自：财华网 ...